Jun Mochizuki

Mr. Jun Mochizuki


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
KIKazuaki Iguchi
Kazuaki Iguchi
KNKoji Nagashima
Koji Nagashima
JMJun Mochizuki
Jun Mochizuki
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
KUKeiko Unno
Keiko Unno
NMNoriyuki Miyoshi
Noriyuki Miyoshi
Several studies have reported the effects of the consumption of various mushroom species on the testes in animal experimental models. Mushrooms, including enokitake mushrooms (Flammulina velutipes), and vegetables contain adenosine may affect testosterone production. Here, we aimed to elucidate the effects of enokitake and its active component, adenosine, on testosterone production in primary cultures of testicular cells in vivo using mice models and in vitro. The administration of enokitake ethanolic extract increased testosterone production in the cisplatin-impaired mouse model. The direct effect of mushroom extracts on testicular cells was examined and liquid chromatography–mass spectrometry analysis confirmed that the mushroom- and vegetable-induced increase in testosterone production mainly involved adenosine. Additionally, the administration of enokitake extract or adenosine to wet floor fatigue model mice promoted testicular testosterone production and enhanced Leydig cell function through insulin-like peptide three level upregulation. Structurally related compounds, including cordycepin, showed lower bioactivity than adenosine. This study showed that the ingestion of adenosine-containing mushrooms and vegetables may effectively increase testicular testosterone production. We conclude that mushrooms with a relatively high adenosine content, such as enokitake, may be useful against aging and fatigue.

30 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
Shizuo YamadaShizuo Yamada
Shizuo Yamada
MSMichiyo Shirai
Michiyo Shirai
KNKoji Nagashima
Koji Nagashima
JMJun Mochizuki
Jun Mochizuki
KOKen Ono
Ken Ono
SKShinji Kageyama
Shinji Kageyama
With the increase in average life expectancy, age-related male menopause has become a cause of decreased quality of life in men. The present study investigated the efficacy and safety of powdered enoki mushroom extract containing adenosine (test food) for menopausal symptoms in middle-aged and elderly men based on an evaluation of Heinemann’s Aging Males’ Symptoms (AMS) scores. The test food and placebo were administered to healthy men with AMS scores of 27–49 for 12 weeks. AMS score (primary endpoint) and testosterone level (secondary endpoint) were evaluated before and 12 weeks after the intake of the test food and placebo. The intake of the test food for 12 weeks significantly improved the sexual subscale of the AMS. In the cumulative χ2 test, the number of subjects showing high improvement was significantly higher in the test food group than in the placebo food group. In a stratified analysis of subjects divided into two groups based on a change in total testosterone levels of <0.5 ng/mL and ≥0.5 ng/mL after the intake of the test food, the number of subjects with increased total testosterone levels of ≥0.5 ng/mL was significantly higher in the test food group than in the placebo group. These results suggest the beneficial effects of enoki mushroom extract on symptoms of male menopause.

15 July 2025
Verified
Book Chapter
Open access
PDF file
SWShaw Watanabe
Shaw Watanabe
SWShu Wakino
Shu Wakino
YSYasushi Saiga
Yasushi Saiga
KFKatsuhiko Fukuda
Katsuhiko Fukuda
JMJun Mochizuki
Jun Mochizuki
HRHaerani Rasyid
Haerani Rasyid
The number of chronic kidney disease (CKD) patients continues to increase globally, according to the increases in obesity, diabetes mellitus, hypertension, and aged people. When the glomerular lesions progress, it can lead to end-stage renal disease, which requires hemodialysis or transplantation. It is historically proven that a low-protein diet is effective for the palliative treatment of uremia. Current drug therapy targeting kidney lesions is insufficient, while dietary therapy is rather ignorant. We developed a low-protein processed genmai (brown rice) (LPPG) to improve CKD management. The essential functional features of brown rice are retained in LPPG and ameliorate the negative spiral of gut-kidney linkage caused by uremic dysbiosis and a leaky gut. LPPG is characterized by an energy value the same as white rice, a protein content of less than 0.2 g/100 g boiled rice, a potassium content that is almost zero, phosphorus of less than a quarter that of conventional rice, the presence of dietary fiber, γ-oryzanol, and antioxidant activity. We tried to clarify the functional mechanism to decrease uremic toxins by improvement of dysbiosis of the colonic microbiota, changes in short-chain fatty acids, and decreased uremic toxins and inflammatory biomarkers through pro- and post-intervention clinical trials in Japan, China, and Indonesia. Changes in microbiota were essential, with increased Firmicutes and decreased Proteobacteria at the phylum level, and Blautia played the essential role for gut microbiota reconstruction at the genus level. We propose a new personalized therapy with LPPG for all stages of CKD patients by decreasing uremic toxins and hidden inflammation.